Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Amgen has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $400.0 million in Q3 2025.

• On a quarterly basis, Asset Writedowns and Impairment rose 555.74% year-over-year to $400.0 million in Q3 2025; TTM through Jun 2026 was $400.0 million, a 55.11% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 654.72% from the prior year.
• Asset Writedowns and Impairment was $400.0 million for Q3 2025 at Amgen, down from $800.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $851.0 million in Q4 2023, with the low at $2.0 million in Q4 2022.
• Average Asset Writedowns and Impairment over 4 years is $277.1 million, with a median of $64.5 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 42450.0% in 2023, then slumped 96.47% in 2024.
• Over 4 years, Asset Writedowns and Impairment stood at $2.0 million in 2022, then jumped by 42450.0% to $851.0 million in 2023, then plunged by 96.47% to $30.0 million in 2024, then surged by 1233.33% to $400.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $400.0 million (Q3 2025), $800.0 million (Q1 2025), and $30.0 million (Q4 2024), per Business Quant data.